CNS Pharmaceuticals, Inc. (CNSP)
Stock Price:
$1.77 USD
-0.07 (-3.80%)
Updated Oct 28, 2020 10:34 AM EDT - Market open
Key Info
| Market Cap |
29.47M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-7.68M |
| Shares Out |
16.65M |
| EPS (ttm) |
-0.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$1.77 |
| Previous Close |
$1.84 |
| Change ($) |
-0.07 |
| Change (%) |
-3.80% |
| Day's Open |
1.84 |
| Day's Range |
1.75 - 1.81 |
| Day's Volume |
6,654 |
| 52-Week Range |
1.26 - 5.69 |
More Stats
| Market Cap |
29.47M |
| Enterprise Value |
26.85M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.65M |
| Float |
6.55M |
| EPS (basic) |
-0.50 |
| EPS (diluted) |
-0.64 |
| FCF / Share |
-0.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
85,382 |
| Short Ratio |
2.26 |
| Short % of Float |
1.30% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
8.29 |
| Revenue |
n/a |
| Operating Income |
-7.66M |
| Net Income |
-7.68M |
| Free Cash Flow |
-7.48M |
| Net Cash |
2.63M |
| Net Cash / Share |
0.16 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-170.24% |
| ROE |
-374.22% |
| ROIC |
-2,263.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.50*
(436.72% upside)
Low
8.00
Current: $1.77
High
11.00
Target: 9.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -3.83 | -0.88 |
| Net Income | -3.88 | -7.39 |
| Shares Outstanding | 13.65 | 10.51 |
| Earnings Per Share | -0.28 | -0.70 |
| Operating Cash Flow | -3.55 | -0.72 |
| Capital Expenditures | -0.02 | - |
| Free Cash Flow | -3.57 | -0.72 |
| Cash & Equivalents | 7.24 | 0.56 |
| Total Debt | - | 0.32 |
| Net Cash / Debt | 7.24 | 0.24 |
| Assets | 7.91 | 0.68 |
| Liabilities | 0.31 | 1.23 |
| Book Value | 7.60 | -0.55 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CNS Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
3 |
| CEO |
John M. Climaco |
Stock Information
| Ticker Symbol |
CNSP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CNSP |
| IPO Date |
November 8, 2019 |
Description
CNS Pharmaceuticals, a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.